Loading stock data…
Neurocrine Biosciences, Inc. (NBIX)
$155.13-0.51 (-0.33%)
Market ClosedLast close Sep 8
Neurocrine Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neurocrine Biosciences, Inc. in the Healthcare sector is trading at $155.13 with a market capitalization of $15.5B. Wall Street consensus targets $211.72 (27 analysts), implying a +36.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $186.12, remaining 5.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $959.00M↑ | $814.50M↑ | $805.50M↑ | $794.90M↑ | $687.50M |
| Gross Profit | $935.80M↑ | $800.70M↑ | $787.90M↑ | $780.90M↑ | $677.20M |
| Operating Income | $153.00M↓ | $186.00M↓ | $227.90M↓ | $239.30M↑ | $145.60M |
| Net Income | $144.40M↓ | $197.90M↑ | $153.70M↓ | $209.50M↑ | $107.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.52B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.10%
Volume
Today's trading volume
818,660
Recent News
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciatio
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
Neurocrine Biosciences (NBIX) drew investor attention after the FDA accepted its Investigational New Drug application for a Phase 2 trial of NBI-1117567 in Alzheimer’s cognition, marking a fresh clinical milestone in its Nxera partnership. Despite the FDA news, Neurocrine Biosciences’ recent 30 day share price return is down 14.72%. However, the year to date share price return of 10.90% and 1 year total shareholder return of 12.22% point to momentum that has built over a longer horizon. Scan...
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer’s cognition, triggering a US$10,000,000 milestone payment to Nxera in Third Quarter Fiscal Year 2026. This IND milestone advances Neurocrine’s broader muscarinic receptor collaboration with Nxera, underscoring its push into Alzheimer’s-related cognitive symptoms alongside existing...
Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds
Neurocrine Biosciences stock has delivered a solid 5 year return while recent trading has been more mixed, and the current share price around US$156 still raises the question of how much value is already reflected. With the broader valuation checks leaning supportive and the market multiples screening as roughly in line with peers, investors are weighing whether the stock still offers an attractive entry point. Over the past 5 years Neurocrine Biosciences has returned 63.8%, which puts the...